Evaluating Micropulse Laser Treatment for Central Serous Chorioretinopathy
Central Serous Chorioretinopathy and Micropulse Laser Treatment: Evaluation of Morphological and Functional Recovery
This study is testing if a special laser treatment can help people with central serous chorioretinopathy who haven't improved with other medications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 36 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Locations | 1 site (Roma, R) |
| Trial ID | NCT06346405 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess changes in the choroidal and choriocapillaris layers in patients diagnosed with central serous chorioretinopathy (CSC) who have not responded to conservative treatments with Acetazolamide and/or Eplerenone. Participants will have experienced foveal serous retinal detachment for at least six months and will undergo subthreshold micropulse laser treatment. The study will focus on understanding the effectiveness of this laser treatment in improving the condition after conservative therapy has failed.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a diagnosis of central serous chorioretinopathy who have not responded to previous conservative treatments.
Not a fit: Patients with previous retinal treatments for CSC or other significant ocular diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with persistent central serous chorioretinopathy.
How similar studies have performed: While there is limited data on the specific use of micropulse laser treatment for CSC, similar laser treatments have shown promise in other retinal conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of central serous chorioretinopathy (CSC) with no response to conservative therapy, consisted in Acetazolamide and Eplerenone after six months. * Foveal serous retinal detachment for at least 6 months. * Minimum age of 18 years old at the screening time * Reading and comprehension skills of informed consent Exclusion Criteria: * Previous retinal treatment for CSC, except for Acetazolamide and Eplerenone * No diffuse retinal epitheliopathy * Other concomitant ocular diseases, such as age related macular degeneration, diabetic retinopathy, choroidal neovascularization * Not controlled glaucoma with eyedrops, or advanced glaucoma * Myopia or hypermetropia greater than 6 diopters * Opacities of dioptric media * Low quality of optical coherence tomography (OCT) and OCT-Angiography scans * Low quality images of Fluorescein angiography and indocyanine green angiography * No written consensus signed.
Where this trial is running
Roma, R
- Fondazione Policlinico Agostino Gemelli, IRCCS — Roma, R, Italy (Recruiting)
Study contacts
- Study coordinator: Maria Cristina Savastano, MD, PhD
- Email: mariacristinasavastano@policlinicogemelli.it
- Phone: (+39)063015
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.